|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram L, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
|
|
2
|
Joshi SS and Badgwell BD: Current
treatment and recent progress in gastric cancer. CA Cancer J Clin.
71:264–279. 2021.
|
|
3
|
Marano L and Roviello F: The distinctive
nature of HER2-positive gastric cancers. Eur J Surg Oncol.
41:271–273. 2015.
|
|
4
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Cooke D, Corvera C, Das R Enzinger PC, Enzler T, Fanta R, et al:
Gastric cancer, version 2.2022, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 20:167–192. 2022.
|
|
5
|
Moasser MM: The oncogene HER2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007.
|
|
6
|
Palle J, Rochand A, Pernot S, Gallois C,
Taieb J and Zaanan A: Human epidermal growth factor receptor 2
(HER2) in advanced gastric cancer: Current knowledge and future
perspectives. Drugs. 80:401–415. 2020.
|
|
7
|
Yang HY, Zhou BP, Hung MC and Lee MH:
Oncogenic signals of HER-2/neu in regulating the stability of the
cyclin-dependent kinase inhibitor p27. J Biol Chem.
275:24735–24739. 2000.
|
|
8
|
Yang ZY, Zhao YW, Xue JR, Guo R, Zhao Z,
Liu HD, Ren ZG and Shi M: Thioridazine reverses trastuzumab
resistance in gastric cancer by inhibiting S-phase kinase
associated protein 2-mediated aerobic glycolysis. World J
Gastroentero. 29:5974–5987. 2023.
|
|
9
|
Lane HA, Motoyama AB, Beuvink I and Hynes
NE: Modulation of p27/Cdk2 complex formation through 4D5-mediated
inhibition of HER2 receptor signaling. Ann Oncol. 12(Suppl 1):
S21–S22. 2001.
|
|
10
|
Kwon HJ, Park Y, Nam SK, Kang E, Kim KK,
Jeong I, Kwak Y, Yoon J, Kim TY, Lee KW, et al: Genetic and immune
microenvironment characterization of HER2-positive gastric cancer:
Their association with response to trastuzumab-based treatment.
Cancer Med. 12:10371–10384. 2023.
|
|
11
|
Yao X, He Z, Qin C, Zhang P, Sui C, Deng
X, Fang Y, Li G and Shi J: Inhibition of PFKFB3 in HER2-positive
gastric cancer improves sensitivity to trastuzumab by inducing
tumour vessel normalisation. Brit J Cancer. 127:811–823. 2022.
|
|
12
|
Kim BJ, Jee HJ, Rha SY, Han HS, Ryu MH,
Park SH, Kim JG, Bae WK, Lee KW, Oh DY, et al: Ramucirumab plus
paclitaxel as a second-line treatment in HER2-positive gastric
cancer: Subgroup analysis of a nationwide, real-world study in
Korea (KCSG-ST19-16). Gastric Cancer. 25:609–618. 2022.
|
|
13
|
Kim Y, Bae YJ, Kim JH, Kim H, Shin SJ,
Jung DH and Park H: Wnt/β-catenin pathway is a key signaling
pathway to trastuzumab resistance in gastric cancer cells. BMC
Cancer. 23:9222023.
|
|
14
|
De Re V, Alessandrini L, Brisotto G,
Caggiari L, De Zorzi M, Casarotto M, Miolo G, Puglisi F, Garattini
SK, Lonardi S, et al: HER2-CDH1 interaction via Wnt/B-catenin is
associated with Patients' survival in HER2-positive metastatic
gastric adenocarcinoma. Cancers (Basel). 14:12662022.
|
|
15
|
Kumagai S, Koyama S and Nishikawa H:
Antitumour immunity regulated by aberrant ERBB family signalling.
Nat Rev Cancer. 21:181–197. 2021.
|
|
16
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697.
2010.
|
|
17
|
Piro G, Carbone C, Cataldo I, Di
Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F,
Zanotto M, Mina MM, et al: An FGFR3, Autocrine loop sustains
acquired resistance to trastuzumab in gastric cancer patients. Clin
Cancer Res. 22:6164–6175. 2016.
|
|
18
|
Xu Q, Xu X, Tang H, Yan J, Li J, Bao H, Wu
X, Shao Y, Luo C, Wen H, et al: Exploring potential molecular
resistance and clonal evolution in advanced HER2-positive gastric
cancer under trastuzumab therapy. Oncogenesis. 12:212023.
|
|
19
|
Zhu Y, Zhu X, Wei X, Tang C and Zhang W:
HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev
Cancer. 1876:1885492021.
|
|
20
|
Shitara K, Bang YJ, Iwasa S, Sugimoto N,
Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al:
Trastuzumab Deruxtecan in previously treated HER2-positive gastric
cancer. New Engl J Med. 382:2419–2430. 2020.
|
|
21
|
Peng Z, Liu T, Wei J, Wang A, He Y, Yang
L, Zhang X, Fan N, Luo S, Gong J, et al: A phase II study of
efficacy and safety of RC48-ADC in patients with locally advanced
or metastatic HER2-overexpressing gastric or gastroesophageal
junction cancers. J Clin Oncol. 38(Suppl 15): S45602020.
|
|
22
|
Lin W, Zhang Y, Yang Y, Lin B, Zhu M, Xu
J, Chen Y, Wu W, Chen B, Chen X, et al: Anti-PD-1/Her2 Bispecific
antibody IBI315 enhances the treatment effect of Her2-positive
gastric cancer through Gasdermin B-cleavage induced Pyroptosis. Adv
Sci. 10:e23039082023.
|
|
23
|
Ogitani Y, Aida T, Hagihara K, Yamaguchi
J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et
al: DS-8201a, A novel HER2-targeting ADC with a Novel DNA
Topoisomerase I inhibitor, demonstrates a promising antitumor
efficacy with differentiation from T-DM1. Clin Cancer Res.
22:5097–5108. 2016.
|
|
24
|
Li L, Xu MZ, Wang L, Jiang J, Dong LH,
Chen F, Dong K and Song HF: Conjugating MMAE to a novel anti-HER2
antibody for selective targeted delivery. Eur Rev Med Pharmaco.
24:12929–12937. 2020.
|
|
25
|
Agus DB, Akita RW, Fox WD, Lewis GD,
Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K,
et al: Targeting ligand-activated ErbB2 signaling inhibits breast
and prostate tumor growth. Cancer Cell. 2:127–137. 2002.
|
|
26
|
Nordstrom JL, Muth J, Erskine CL, Sanders
C, Yusko EC, Emerson RO, Lee M, Lee S, Trepel JB, Im S, et al: High
frequency of HER2-specific immunity observed in patients (pts) with
HER2+cancers treated with margetuximab (M), an Fc-enhanced
anti-HER2 monoclonal antibody (mAb). J Clin Oncol. 37(Suppl 15):
S10302019.
|
|
27
|
Yu S, Liu Q, Han X, Qin S, Zhao W, Li A
and Wu K: Development and clinical application of anti-HER2
monoclonal and bispecific antibodies for cancer treatment. Exp
Hematol Oncol. 6:312017.
|
|
28
|
Labrijn AF, Janmaat ML, Reichert JM and
Parren P: Bispecific antibodies: A mechanistic review of the
pipeline. Nat Rev Drug Discov. 18:585–608. 2019.
|
|
29
|
Lewis PG, Li G, Dugger DL, Crocker LM,
Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, et
al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an
anti-body-cytotoxic drug conjugate. Cancer Res. 68:9280–9290.
2008.
|
|
30
|
Humphreys RC, Kirtely J, Hewit A, Biroc S,
Knudsen N, Skidmore L and Wahl A: Abstract 639: Site specific
conjugation of ARX-788, an antibody drug conjugate (ADC) targeting
HER2, generates a potent and stable targeted therapeutic for
multiple cancers. Cancer Res. 75:6392015.
|
|
31
|
Johnston SRD and Leary A: Lapatinib: A
novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drug Today.
42:441–453. 2006.
|
|
32
|
Zhu Y, Li L, Zhang G, Wan H, Yang C, Diao
X, Chen X, Zhang L and Zhong D: Metabolic characterization of
pyrotinib in humans by ultra-performance liquid
chromatography/quadrupole time-of-flight mass spectrometry. J
Chromatogr B Analyt Technol Biomed Life Sci. 1033-1034:117–127.
2016.
|
|
33
|
Doi AGL, Lindmark BE, McHale M, Hung HT
and Ong R: Abstract 4719: Varlitinib demonstrates potent antitumor
efficacy in patient-derived gastric cancer xenograft models. Cancer
Res. 76:47192016.
|
|
34
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos BA, et al: First-line nivolumab plus chemotherapy versus
chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
|
|
35
|
Janjigian YY, Kawazoe A, Yanez P, Li N,
Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, et al: The
KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive
gastric cancer. Nature. 600:727–730. 2021.
|
|
36
|
Huang L, Wang R, Xie K, Zhang J, Tao F, Pi
C, Feng Y, Gu H and Fang J: A HER2 target antibody drug conjugate
combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in
hPD-1 transgenic mouse model and contributes immune memory
formation. Breast Cancer Res Treat. 191:51–61. 2022.
|
|
37
|
Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge
W, Cui Q, Mu Q, Chen G, Han L, et al: Genetically modified
CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy
for relapsed/refractory CD7-positive hematological malignancies: A
phase I clinical study. Cell Res. 32:995–1007. 2022.
|
|
38
|
Lu J and Jiang G: The journey of CAR-T
therapy in hematological malignancies. Mol Cancer. 21:1942022.
|
|
39
|
Hou AJ, Chen LC and Chen YY: Navigating
CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug
Discov. 20:531–550. 2021.
|
|
40
|
Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo
Y, Zhao X, Wang Y, Wang Z, Han W, et al: Effective and persistent
antitumor activity of HER2-directed CAR-T cells against gastric
cancer cells in vitro and xenotransplanted tumors in vivo. Protein
Cell. 9:867–878. 2018.
|
|
41
|
Vivekanandhan S and Knutson KL: Resistance
to trastuzumab. Cancers (Basel). 14:51152022.
|
|
42
|
Hino K, Nishina T, Kajiwara T, Bando H,
Nakamura M, Kadowaki S, Minashi K, Yuki S, Ohta T, Hara H, et al:
Association of ERBB2 copy number and gene coalterations with
trastuzumab efficacy and resistance in human epidermal growth
factor receptor 2-Positive Esophagogastric and gastric cancer. JCO
Precis Oncol. 6:e22001352022.
|
|
43
|
Du R, Zhang X, Lu X, Ma X, Guo X, Shi C,
Ren X, Ma X, He Y, Gao Y and Liu Y: PDPN positive CAFs contribute
to HER2 positive breast cancer resistance to trastuzumab by
inhibiting antibody-dependent NK cell-mediated cytotoxicity. Drug
Resist Updat. 68:1009472023.
|
|
44
|
Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng
ZL, Liu Z, Zhao Q, He CY, Lu JH, et al: Liquid biopsies to track
trastuzumab resistance in metastatic HER2-positive gastric cancer.
Gut. 68:1152–1161. 2019.
|
|
45
|
Wang H, Li B, Liu Z, Gong J, Shao L, Ren
J, Niu Y, Bo S, Li Z, Lai Y, et al: HER2 copy number of circulating
tumour DNA functions as a biomarker to predict and monitor
trastuzumab efficacy in advanced gastric cancer. Eur J Cancer.
88:92–100. 2018.
|
|
46
|
Wang S, Khan S, Nabi G and Li HY:
Circadian rhythm as a key player in cancer progression as well as a
therapeutic target in HER2-positive advanced gastric cancer
treatment. Front Oncol. 13:12406762023.
|
|
47
|
Wang J, Huang Q, Hu X, Zhang S, Jiang Y,
Yao G, Hu K, Xu X, Liang B, Wu Q, et al: Disrupting circadian
rhythm via the PER1-HK2 axis reverses trastuzumab resistance in
gastric cancer. Cancer Res. 82:1503–1517. 2022.
|
|
48
|
Wang J, Kunzke T, Prade VM, Shen J, Buck
A, Feuchtinger A, Haffner I, Luber B, Liu D, Langer R, et al:
Spatial metabolomics identifies distinct tumor-specific subtypes in
gastric cancer patients. Clin Cancer Res. 28:2865–2877. 2022.
|
|
49
|
Wang J, Tu S, Chavda VP, Chen ZS and Chen
X: Successes and failures of immunotherapy for gastric cancer. Drug
Discov Today. 27:1033432022.
|
|
50
|
Yang Y: Cancer immunotherapy: Harnessing
the immune system to battle cancer. J Clin Invest. 125:3335–3337.
2015.
|
|
51
|
Riley RS, June CH, Langer R and Mitchell
MJ: Delivery technologies for cancer immunotherapy. Nat Rev Drug
Discov. 18:175–196. 2019.
|
|
52
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000.
|
|
53
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020.
|
|
54
|
Goel G and Sun W: Cancer immunotherapy in
clinical practice-the past, present, and future. Chin J Cancer.
33:445–457. 2014.
|
|
55
|
Pang K, Shi ZD, Wei LY, Dong Y, Ma YY,
Wang W, Wang GY, Cao MY, Dong JJ, Chen YA, et al: Research progress
of therapeutic effects and drug resistance of immunotherapy based
on PD-1/PD-L1 blockade. Drug Resist Updat. 66:1009072023.
|
|
56
|
Stein A, Paschold L, Tintelnot J, Goekkurt
E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M,
Wickenhauser C, et al: Efficacy of ipilimumab vs FOLFOX in
combination with nivolumab and trastuzumab in patients with
previously untreated ERBB2-positive Esophagogastric adenocarcinoma:
The AIO INTEGA randomized clinical trial. JAMA Oncol. 8:1150–1158.
2022.
|
|
57
|
Aisa A, Weng S, Li X, Zhang D and Yuan Y:
Immune checkpoint inhibitors combined with HER-2 targeted therapy
in HER-2 positive gastroesophageal cancer. Crit Rev Oncol Hemat.
180:1038642022.
|
|
58
|
Agostinetto E, Montemurro F, Puglisi F,
Criscitiello C, Bianchini G, Del ML, Introna M, Tondini C, Santoro
A and Zambelli A: Immunotherapy for HER2-positive breast cancer:
Clinical evidence and future perspectives. Cancers (Basel).
14:21362022.
|
|
59
|
Rha SY, Lee C, Kim HS, Kang B, Jung M,
Kwon WS, Bae WK, Koo D, Shin S, Jeung H, et al: A
multi-institutional phase Ib/II trial of first-line triplet regimen
(Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive
advanced gastric and gastroesophageal junction cancer (PANTHERA
Trial): Molecular profiling and clinical update. J Clin Oncol.
39(Suppl 3): S2182021.
|
|
60
|
Janjigian YY, Maron SB, Chatila WK,
Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ,
Momtaz P, et al: First-line pembrolizumab and trastuzumab in
HER2-positive oesophageal, gastric, or gastro-oesophageal junction
cancer: An open-label, single-arm, phase 2 trial. Lancet Oncol.
21:821–831. 2020.
|
|
61
|
Chung HC, Bang Y, S Fuchs C, Qin SK, Satoh
T, Shitara K, Tabernero J, Cutsem EV, Alsina M, Cao ZA, et al:
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy
in HER2-positive advanced gastric cancer: KEYNOTE-811. Future
Oncol. 17:491–501. 2021.
|
|
62
|
Killock D: Pembrolizumab for
HER2+ gastric cancer. Nat Rev Clin Oncol.
19:1502022.
|
|
63
|
Kuznetsova M, Lopatnikova J, Shevchenko J,
Silkov A, Maksyutov A and Sennikov S: Cytotoxic activity and memory
T cell subset distribution of in vitro-Stimulated CD8+ T
cells specific for HER2/neu Epitopes. Front Immunol.
10:10172019.
|
|
64
|
Müller P, Kreuzaler M, Khan T, Thommen DS,
Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, et al:
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly
susceptible to CTLA-4/PD-1 blockade. Sci Transl Med.
7:315ra1882015.
|
|
65
|
Stagg J, Loi S, Divisekera U, Ngiow SF,
Duret H, Yagita H, Teng MW and Smyth MJ: Anti-ErbB-2 mAb therapy
requires type I and II interferons and synergizes with anti-PD-1 or
anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 108:7142–7147.
2011.
|
|
66
|
Takahari D, Wakatsuki T, Ishizuka N,
Fukuda N, Shoji H, Hara H, Minashi K, Boku N and Yamaguchi K: A
phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine
plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH
study): Safety evaluation. J Clin Oncol. 38:45252020.
|
|
67
|
Takahari D, Shoji H, Minashi K, Hara H,
Chin K, Oki A, Ogura M, Nakayama I, Kato K, Iwasa S, et al: Safety
and early efficacy results of a phase Ib study of nivolumab plus
trastuzumab with S-1/capecitabine plus oxaliplatin for
HER2-positive advanced gastric cancer (Ni-HIGH study). J Clin
Oncol. 40:2762022.
|
|
68
|
Tintelnot J, Goekkurt E, Binder M,
Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A,
Ettrich T, Lindig U, Jacobasch L, et al: Ipilimumab or FOLFOX with
Nivolumab and Trastuzumab in previously untreated HER2-positive
locally advanced or metastatic EsophagoGastric Adenocarcinoma-the
randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer.
20:5032020.
|
|
69
|
Lee MS, Chao J, Mulcahy MF, Kasi PM,
Alistar AT, Mukherjee S, Akce M, Moore DT, Carlson CA and Mcree AJ:
Abstract CT174: Phase II study of avelumab and trastuzumab with
FOLFOX chemotherapy in previously untreated HER2-amplified
metastatic gastroesophageal adenocarcinoma. Cancer Res.
81:CT1742021.
|
|
70
|
Makiyama A, Sukawa Y, Kashiwada T, Kawada
J, Hosokawa A, Horie Y, Tsuji A, Moriwaki T, Tanioka H, Shinozaki
K, et al: Randomized, Phase II study of trastuzumab beyond
progression in patients with HER2-positive advanced gastric or
gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin
Oncol. 38:1919–1927. 2020.
|
|
71
|
Kim CG, Jung M, Kim HS, Lee CK, Jeung HC,
Koo DH, Bae WK, Zang DY, Kim BJ, Kim H, et al: Trastuzumab combined
with ramucirumab and paclitaxel in patients with previously treated
human epidermal growth factor receptor 2-positive advanced gastric
or gastroesophageal junction cancer. J Clin Oncol. 41:4394–4405.
2023.
|
|
72
|
Ogitani Y, Hagihara K, Oitate M, Naito H
and Agatsuma T: Bystander killing effect of DS-8201a, a novel
anti-human epidermal growth factor receptor 2 antibody-drug
conjugate, in tumors with human epidermal growth factor receptor 2
heterogeneity. Cancer Sci. 107:1039–1046. 2016.
|
|
73
|
Doi T, Shitara K, Naito Y, Shimomura A,
Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N,
et al: Safety, pharmacokinetics, and antitumour activity of
trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug
conjugate, in patients with advanced breast and gastric or
gastro-oesophageal tumours: A phase 1 dose-escalation study. Lancet
Oncol. 18:1512–1522. 2017.
|
|
74
|
Shitara K, Iwata H, Takahashi S, Tamura K,
Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, et
al: Trastuzumab deruxtecan (DS-8201a) in patients with advanced
HER2-positive gastric cancer: A dose-expansion, phase 1 study.
Lancet Oncol. 20:827–836. 2019.
|
|
75
|
Staudacher AH and Brown MP: Antibody drug
conjugates and bystander killing: Is antigen-dependent
internalisation required? Brit J Cancer. 117:1736–1742. 2017.
|
|
76
|
Xu Y, Wang Y, Gong J, Zhang X, Peng Z,
Sheng X, Mao C, Fan Q, Bai Y, Ba Y, et al: Phase I study of the
recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate
RC48-ADC in patients with HER2-positive advanced solid tumors.
Gastric Cancer. 24:913–925. 2021.
|
|
77
|
Thuss-Patience PC, Shah MA, Ohtsu A, Van
Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G,
Shitara K, et al: Trastuzumab emtansine versus taxane use for
previously treated HER2-positive locally advanced or metastatic
gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An
international randomised, open-label, adaptive, phase 2/3 study.
Lancet Oncol. 18:640–653. 2017.
|
|
78
|
Xu J, Ying J, Liu R, Wu J, Ye F, Xu N,
Zhang Y, Zhao R, Xiang X, Wang J, et al: KN026 (anti-HER2
bispecific antibody) in patients with previously treated, advanced
HER2-expressing gastric or gastroesophageal junction cancer. Eur J
Cancer. 178:1–12. 2023.
|
|
79
|
Meric-Bernstam F, Hamilton EP, Beeram M,
Hanna DL, El-Khoueiry AB, Kang Y, Lee KW, Lee J, Rha SY, Chaves JM,
et al: Zanidatamab (ZW25) in HER2-expressing gastroesophageal
adenocarcinoma (GEA): Results from a phase I study. J Clin Oncol.
39(Suppl 3): S1642021.
|
|
80
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges J, et al: Safety and
efficacy of Pembrolizumab Monotherapy in patients with previously
treated advanced gastric and Gastroesophageal junction cancer. JAMA
Oncol. 4:e1800132018.
|
|
81
|
Shitara K, Özguroglu M, Bang YJ, Di
Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic
C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously
treated, advanced gastric or gastro-oesophageal junction cancer
(KEYNO TE-061): A randomised, open-label, controlled, phase 3
trial. Lancet. 392:123–133. 2018.
|
|
82
|
Catenacci D, Kang YK, Park H, Uronis HE,
Lee KW, Ng M, Enzinger PC, Park SH, Gold PJ, Lacy J, et al:
Margetuximab plus pembrolizumab in patients with previously
treated, HER2-positive gastro-oesophageal adenocarcinoma
(CP-MGAH22-05): A single-arm, phase 1b-2 trial. Lancet Oncol.
21:1066–1076. 2020.
|
|
83
|
Swain SM, Miles D, Kim SB, Im YH, Im SA,
Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, et al:
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic
breast cancer (CLEOPATRA): End-of-study results from a
double-blind, randomised, placebo-controlled, phase 3 study. Lancet
Oncol. 21:519–530. 2020.
|
|
84
|
Yamashita-Kashima Y, Iijima S, Yorozu K,
Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in
combination with trastuzumab shows significantly enhanced antitumor
activity in HER2-positive human gastric cancer xenograft models.
Clin Cancer Res. 17:5060–5070. 2011.
|
|
85
|
Tabernero J, Hoff PM, Shen L, Ohtsu A,
Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, et al:
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive
metastatic gastric or gastro-oesophageal junction cancer (JACOB).
Final analysis of a double-blind, randomised, placebo-controlled
phase 3 study. Lancet Oncol. 19:1372–1384. 2018.
|
|
86
|
Liu T, Qin Y, Li J, Xu R, Xu J, Yang S,
Qin S, Bai Y, Wu C, Mao Y, et al: Pertuzumab in combination with
trastuzumab and chemotherapy for Chinese patients with
HER2-positive metastatic gastric or gastroesophageal junction
cancer. A subpopulation analysis of the JACOB trial. Cancer Commun
(Lond). 39:382019.
|
|
87
|
Wagner AD, Grabsch HI, Mauer M, Marreaud
S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH,
Martens U, et al: EORTC-1203-GITCG-the 'INNOVATION'-trial: Effect
of chemotherapy alone versus chemotherapy plus trastuzumab, versus
chemotherapy plus trastuzumab plus pertuzumab, in the perioperative
treatment of HER2 positive, gastric and gastroesophageal junction
adenocarcinoma on pathologic response rate: A randomized phase
II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer
Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
BMC Cancer. 19:4942019.
|
|
88
|
Nordstrom JL, Gorlatov S, Zhang W, Yang Y,
Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, et al:
Anti-tumor activity and toxicokinetics analysis of MGAH22, an
anti-HER2 monoclonal antibody with enhanced Fcgamma receptor
binding properties. Breast Cancer Res. 13:R1232011.
|
|
89
|
Bang YJ, Giaccone G, Im SA, Oh DY, Bauer
TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, et al:
First-in-human phase 1 study of margetuximab (MGAH22), an
Fc-modified chimeric monoclonal antibody, in patients with
HER2-positive advanced solid tumors. Ann Oncol. 28:855–861.
2017.
|
|
90
|
Rugo HS, Im SA, Cardoso F, Cortes J,
Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C,
Escriva-de-Romani S, et al: Efficacy of Margetuximab vs trastuzumab
in patients with pretreated ERBB2-positive advanced breast cancer.
A phase 3 randomized clinical trial. JAMA Oncol. 7:573–584.
2021.
|
|
91
|
Catenacci DVT, Kim SS, Gold PJ, Philip AP,
Enzinger PC, Coffie J, Schmidt EV, Baldwin M, Nordstrom JL, Bonvini
E, et al: A phase 1b/2, open label, dose-escalation study of
margetuximab (M) in combination with pembrolizumab (P) in patients
with relapsed/refractory advanced HER2+ gastroesophageal (GEJ)
junction or gastric (G) cancer. J Clin Oncol. 35(Suppl 4):
TPS2192017.
|
|
92
|
Catenacci DVT, Park H, Lockhart AC, Gold
PJ, Enzinger PC, Nordstrom JL, Hong S, Hochster HS, Kelly RJ,
Uronis HE, et al: Phase 1b/2 study of margetuximab (M) plus
pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ)
or gastric (G) adenocarcinoma (GEA). J Clin Oncol. 36(Suppl 4):
S1402018.
|
|
93
|
Catenacci DVT, Park H, Uronis HE, Kang Y,
Lacy J, Enzinger PC, Park SH, Lee KW, Ng MCH, Gold PJ, et al:
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified
PD-L1+gastroesophageal adenocarcinoma (GEA) post trastuzumab (T). J
Clin Oncol. 36(Suppl 15): S40302018.
|
|
94
|
Catenacci DVT, Lim KH, Uronis HE, Kang Y,
Ng MCH, Gold PJ, Enzinger PC, Lee KW, Lacy J, Park SH, et al:
Antitumor activity of margetuximab (M) plus pembrolizumab (P) in
patients (pts) with advanced HER2+(IHC3+) gastric carcinoma (GC). J
Clin Oncol. 37(Suppl 4): S652019.
|
|
95
|
Catenacci DVT, Rosales M, Chung HC, Yoon
HH, Shen L, Moehler M and Kang Y: MAHOGANY: margetuximab
combination in HER2(+) unresectable/metastatic
gastric/gastroesophageal junction adenocarcinoma. Future Oncol.
17:1155–1164. 2021.
|
|
96
|
Luke JJ, Patel MR, Blumenschein GR,
Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria
CA, Wang J, Bahadur SW, et al: The PD-1- and LAG-3-targeting
bispecific molecule tebotelimab in solid tumors and hematologic
cancers. A phase 1 trial. Nat Med. 29:2814–2824. 2023.
|
|
97
|
Catenacci DV, Rosales M, Chung HC, H YH,
Shen L, Moehler M and Kang YK: MAHOGANY: Margetuximab combination
in HER2+ unresectable/metastatic Gastric/Gastroesophageal junction
adenocarcinoma. Future Oncol. 17:1155–1164. 2021.
|
|
98
|
Catenacci D, Kang YK, Yoon HH, Shim BY,
Kim ST, Oh DY, Spira AI, Ulahannan SV, Avery EJ, Boland PM, et al:
Margetuximab with retifanlimab as first-line therapy in
HER2+/PD-L1+ unresectable or metastatic gastroesophageal
adenocarcinoma: MAHOGANY cohort A. Esmo Open. 7:1005632022.
|
|
99
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, et al:
Trastuzumab emtansine for HER2-positive advanced breast cancer. New
Engl J Med. 367:1783–1791. 2012.
|
|
100
|
Krop IE, Kim SB, Gonzalez-Martin A,
LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC and Wildiers H:
Trastuzumab emtansine versus treatment of physician's choice for
pretreated HER2-positive advanced breast cancer (TH3RESA). A
randomised, open-label, phase 3 trial. Lancet Oncol. 15:689–699.
2014.
|
|
101
|
Dieras V, Miles D, Verma S, Pegram M,
Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, et al:
Trastuzumab emtansine versus capecitabine plus lapatinib in
patients with previously treated HER2-positive advanced breast
cancer (EMILIA): A descriptive analysis of final overall survival
results from a randomised, open-label, phase 3 trial. Lancet Oncol.
18:732–742. 2017.
|
|
102
|
Li H, Xu X, Liu Y, Li S, Zhang D, Meng X,
Lu L and Li Y: MMP7 induces T-DM1 resistance and leads to the poor
prognosis of gastric adenocarcinoma via a DKK1-dependent manner.
Anticancer Agents Med Chem. 18:2010–2016. 2018.
|
|
103
|
Nagaraja SP, Zhu J, Skidmore L, Liang X,
Ji Y, Gu Y, Tian F, Yao S and Xia G: Nonclinical development of
Next-generation Site-specific HER2-targeting Antibody-drug
Conjugate (ARX788) for breast cancer treatment. Mol Cancer Ther.
19:1822–1832. 2020.
|
|
104
|
Skidmore L, Sakamuri S, Knudsen NA, Hewet
AG, Milutinovic S, Barkho W, Biroc SL, Kirtley J, Marsden R, Storey
K, et al: ARX788, a Site-specific Anti-HER2 Antibody-drug
conjugate, demonstrates potent and selective activity in HER2-low
and T-DM1-resistant breast and gastric cancers. Mol Cancer Ther.
19:1833–1843. 2020.
|
|
105
|
Barok M, Le Joncour V, Martins A, Isola J,
Salmikangas M, Laakkonen P and Joensuu H: ARX788, a novel anti-HER2
antibody-drug conjugate, shows anti-tumor effects in preclinical
models of trastuzumab emtansine-resistant HER2-positive breast
cancer and gastric cancer. Cancer Lett. 473:156–163. 2020.
|
|
106
|
Zhang Y, Qiu MZ, Wang JF, Zhang YQ, Shen
A, Yuan XL, Zhang T, Wei XL, Zhao HY, Wang DS, et al: Phase 1
multicenter, dose-expansion study of ARX788 as monotherapy in
HER2-positive advanced gastric and gastroesophageal junction
adenocarcinoma. Cell Rep Med. 3:1008142022.
|
|
107
|
Weisser N, Wickman G, Davies R and Rowse
G: Preclinical development of a novel biparatopic HER2 antibody
with activity in low to high HER2 expressing cancers. Cancer Res.
77(Suppl 13): S172017.
|
|
108
|
ZW25 Effective in HER2-positive cancers.
Cancer Discov. 9:82019.
|
|
109
|
Meric-Bernstam F, Beeram M, Mayordomo JI,
Hanna DL, Ajani JA, Murphy MAB, Murthy RK, Piha-Paul SA, Bauer TM,
Bendell JC, et al: Single agent activity of ZW25, a HER2-targeted
bispecific antibody, in heavily pretreated HER2-expressing cancers.
J Clin Oncol. 36(15 Suppl): S25002018.
|
|
110
|
Wei H, Cai H, Jin Y, Wang P, Zhang Q, Lin
Y, Wang W, Cheng J, Zeng N, Xu T and Zhou A: Structural basis of a
novel heterodimeric Fc for bispecific antibody production.
Oncotarget. 8:51037–51049. 2017.
|
|
111
|
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang
X, Shen W, Du Y, Pang H, Lai X, et al: First-in-human HER2-targeted
Bispecific Antibody KN026 for the treatment of patients with
HER2-positive metastatic breast cancer: Results from a Phase I
study. Clin Cancer Res. 28:618–628. 2022.
|
|
112
|
Xu J, Zhang Y, Wu J, Xu N, Ying J, Xiang
X, Zhang Y, Wang J, Zhao R, Ye F, et al: The preliminary efficacy
of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal
junction cancer patients with HER2 expression. J Clin Oncol.
39(Suppl 15): e160052021.
|
|
113
|
Gong J, Shen L, Dong Z, Liu D, Xu J, Yang
J, Yang Y, Qi Y, Men J, Kong P, et al: Preliminary safety,
tolerability and efficacy results of KN026 in combination with
KN046 in patients with HER2 aberrated solid tumors. J Immunother
Cancer. 83:A485–A486. 2020.
|
|
114
|
Gong J, Dong Z, Liu D, Xu J, Yang J, Yang
Y, Qi Y, Men J, Kong P, Xu T, et al: Preliminary safety,
tolerability and efficacy results of KN026 (a HER2-targeted
bispecific antibody) in combination with KN046 (an
anti-PD-Ll/CTLA-4 bispecific antibody) in patients (pts) with HER2
aberrated solid tumors. J Immunother Cancer. 83:A2072020.
|
|
115
|
Shen L, Gong J, Niu Z, Zhao R, Chen L, Liu
L, Deng T, Lu L, Zhang Y, Li Z, et al: 1210P the preliminary
efficacy and safety of KN026 combined with KN046 treatment in
HER2-positive locally advanced unresectable or metastatic
gastric/gastroesophageal junction cancer without prior systemic
treatment in a phase II study. Ann Oncol. 33(Suppl 7):
S11022022.
|
|
116
|
Lin W, Zhang Y, Yang Y, Lin B, Zhu M, Xu
J, Chen Y, Wu W, Chen B, Chen X, et al: Anti-PD-1/Her2 bispecific
antibody IBI315 enhances the treatment effect of Her2-positive
gastric cancer through Gasdermin B-cleavage induced pyroptosis. Adv
Sci (Weinh). 10:e23039082023.
|
|
117
|
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu
JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, et al:
Lapatinib in combination with capecitabine plus oxaliplatin in
human epidermal growth factor receptor 2-positive advanced or
metastatic gastric esophageal, or gastroesophageal adenocarcinoma:
TRIO-013/LOGiC-A randomized phase III trial. J Clin Oncol.
34:443–451. 2016.
|
|
118
|
Press MF, Ellis CE, Gagnon RC, Grob TJ,
Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, et al: HER2
status in advanced or metastatic gastric, esophageal, or
gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC
trial of Lapatinib. Mol Cancer Ther. 16:228–238. 2017.
|
|
119
|
Satoh T, Xu RH, Chung HC, Sun GP, Doi T,
Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, et al: Lapatinib plus
paclitaxel versus paclitaxel alone in the second-line treatment of
HER2-amplified advanced gastric cancer in Asian populations:
TyTAN-a randomized, phase III study. J Clin Oncol. 32:2039–2049.
2014.
|
|
120
|
Chen CT, Kim H, Liska D, Gao S,
Christensen JG and Weiser MR: MET activation mediates resistance to
lapatinib inhibition of HER2-amplified gastric cancer cells. Mol
Cancer Ther. 11:660–669. 2012.
|
|
121
|
Ning G, Zhu Q, Kang W, Lee H, Maher L, Suh
Y, Michaud M, Silva M, Kwon JY, Zhang C, et al: A novel treatment
strategy for lapatinib resistance in a subset of HER2-amplified
gastric cancer. BMC Cancer. 21:9232021.
|
|
122
|
Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J,
Luo Y, Xing P, Lan B, Li M, et al: phase I study and biomarker
analysis of pyrotinib, a novel irreversible Pan-ErbB receptor
tyrosine kinase inhibitor, in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer. J Clin Oncol.
35:3105–3112. 2017.
|
|
123
|
Li Q, Guan X, Chen S, Yi Z, Lan B, Xing P,
Fan Y, Wang J, Luo Y, Yuan P, et al: Safety efficacy, and biomarker
analysis of pyrotinib in combination with Capecitabine in
HER2-positive metastatic breast cancer patients: A phase I clinical
trial. Clin Cancer Res. 25:5212–5220. 2019.
|
|
124
|
Yin Y, Yang H, Liu Z, Tan J, Zhu C, Chen
M, Zhou R, Wang L and Qian J: Studies on the safety and efficacy of
pyrotinib in the treatment of HER2-positive advanced solid tumors
excluding breast cancer. Cancer Manag Res. 12:13479–13487.
2020.
|
|
125
|
Fan S, Jiang D, Lv Y, Cui Y and Hou R:
Studies on the efficacy of pyrotinib in the treatment of HER-2
positive advanced solid tumors. J Clin Oncol. 38:e156392020.
|
|
126
|
Liu D, Xu YY, Gong JF, Yang F, Shen L and
Li HJ: Pyrotinib combined with SHR6390 in the treatment of
refractory advanced HER2 positive gastric cancer or solid tumors:
Safety and efficacy results from a phase Id trial. J Clin Oncol.
39(Suppl 15): e160092021.
|
|
127
|
Li X, Gu X, Xu J, Chen L, Li H, Meng D,
Bai H, Yang J and Qian J: Sustained clinical benefit of pyrotinib
combined with capecitabine rescue therapy after trastuzumab
resistance in HER2-positive advanced gastric cancer: A case report.
Oncotargets Ther. 14:3983–3989. 2021.
|
|
128
|
Wu J, Li L, Qin J, Yan Z, Chen S, Jin T
and Xu J: Case report: Durable clinical response to third-line
pyrotinib after resistance to trastuzumab in a gastric cancer
patient. Front Oncol. 11:7805772021.
|
|
129
|
Chen Z, Xu Y, Gong J, Kou F, Zhang M, Tian
T, Zhang X, Zhang C, Li J, Li Z, et al: Pyrotinib combined with
CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A
promising strategy from AVATAR mouse to patients. Clin Transl Med.
10:e1482020.
|
|
130
|
Huang LT, Ma JT, Zhang SL, Li XH, Sun L,
Jing W, Zhao JZ, Wang YR and Han CB: Durable clinical response to
pyrotinib after resistance to prior Anti-HER2 therapy for
HER2-positive advanced gastric cancer: A case report. Front Oncol.
9:14532019.
|
|
131
|
Sang Y, Jung M, Kim HS, Kang B, Lee C,
Chung HC and Rha SY: Phase Ib trial of varlitinib plus weekly
paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer
(AGC). J Clin Oncol. 39(Suppl 3): S2272021.
|
|
132
|
Murthy RK, Loi S, Okines A, Paplomata E,
Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et
al: Tucatinib, trastuzumab, and Capecitabine for HER2-positive
metastatic breast cancer. New Engl J Med. 382:597–609. 2020.
|
|
133
|
Peterson S, de Vries P, Piasecki J and
Rosler R: Tucatinib, a HER2 selective kinase inhibitor, is active
in patient derived xenograft (PDX) models of HER2-amplified
colorectal, esophageal and gastric cancers. Ann Oncol. 28(Suppl 5):
V5762017.
|
|
134
|
Strickler JH, Cercek A, Siena S, Andre T,
Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, et
al: Tucatinib plus trastuzumab for chemotherapy-refractory,
HER2-positive, RAS wild-type unresectable or metastatic colorectal
cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study.
Lancet Oncol. 24:496–508. 2023.
|
|
135
|
Strickler JH, Nakamura Y, Yoshino T,
Catenacci DVT, Janjigian YY, Barzi A, Bekaii-Saab TS, Lenz H, Lee
J, Van Cutsem E, et al: MOUNTAINEER-02: Phase II/III study of
tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously
treated HER2+ gastric or gastroesophageal junction
adenocarcinoma-trial in progress. J Clin Oncol. 39(Suppl 5):
S1071–S1072. 2021.
|
|
136
|
Tabernero J, Strickler J, Nakamura Y,
Shitara K, Janjigian Y, Barzi A, Bekaii-Saab T, Lenz H, Yoshino T,
Siena S, et al: MOUNTAINEER-02: Phase 2/3 study of tucatinib,
trastuzumab, ramucirumab, and paclitaxel in previously treated
HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in
progress. Ann Oncol. 33(Suppl): S305–S306. 2022.
|
|
137
|
Siddiqui RS and Sardar M: A systematic
review of the role of chimeric antigen receptor T (CAR-T) cell
therapy in the treatment of solid tumors. Cureus J Med Science.
13:e144942021.
|
|
138
|
Liu D, Zhao J and Song Y: Engineering
switchable and programmable universal CARs for CAR T therapy. J
Hematol Oncol. 12:692019.
|
|
139
|
Holstein SA and Lunning MA: CAR T-cell
therapy in hematologic malignancies: A voyage in progress. Clin
Pharmacol Ther. 107:112–122. 2020.
|
|
140
|
Munshi NC, Anderson LJ, Shah N, Madduri D,
Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al:
Idecabtagene Vicleucel in relapsed and refractory multiple myeloma.
New Engl J Med. 384:705–716. 2021.
|
|
141
|
Miao YR, Liu W, Zhong Z, You Y, Tang Y, Li
W, Zhu X and Guo AY: Case Report: Multi-Omics analysis and CAR-T
treatment of a chronic myeloid leukemia blast crisis case 5 years
after the discontinuation of TKI. Front Oncol. 11:7398712021.
|
|
142
|
Dana H, Chalbatani GM, Jalali SA, Mirzaei
HR, Grupp SA, Suarez ER, Raposo C and Webster TJ: CAR-T cells:
Early successes in blood cancer and challenges in solid tumors.
Acta Pharm Sin B. 11:1129–1147. 2021.
|
|
143
|
Sun J, Li X, Chen P and Gao Y: From
Anti-HER-2 to Anti-HER-2-CAR-T cells: An evolutionary immunotherapy
approach for gastric cancer. J Inflamm Res. 15:4061–4085. 2022.
|
|
144
|
Han Y, Liu C, Li G, Li J, Lv X, Shi H, Liu
J, Liu S, Yan P, Wang S, et al: Antitumor effects and persistence
of a novel HER2 CAR T cells directed to gastric cancer in
preclinical models. Am J Cancer Res. 8:106–119. 2018.
|
|
145
|
Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H,
Yang Q, Wang Y and Han W: Phase I study of chimeric antigen
receptor modified T cells in treating HER2-positive advanced
biliary tract cancers and pancreatic cancers. Protein Cell.
9:838–847. 2018.
|
|
146
|
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S,
Zhang M, Peng Z, Zhou J, Cao Y, et al: Claudin18.2-specific CAR T
cells in gastrointestinal cancers: Phase 1 trial interim results.
Nat Med. 28:1189–1198. 2022.
|
|
147
|
Simon AG, Lyu SI, Laible M, Woell S,
Tuereci O, Sahin U, Alakus H, Fahrig L, Zander T, Buettner R, et
al: The tight junction protein claudin 6 is a potential target for
patient-individualized treatment in esophageal and gastric
adenocarcinoma and is associated with poor prognosis. J Transl Med.
21:5522023.
|
|
148
|
Entezam M, Sanaei M, Mirzaei Y, Mer AH,
Abdollahpour-Alitappeh M, Azadegan-Dehkordi F and Bagheri N:
Current progress and challenges of immunotherapy in gastric cancer:
A focus on CAR-T cells therapeutic approach. Life Sci.
318:1214592023.
|
|
149
|
Clark RE, Basabrain AA, Austin GM,
Holcroft AK, Loaiza S, Apperley JF, Law C, Scott L, Parry AD,
Bonnett L, et al: Validation of CIP2A as a biomarker of subsequent
disease progression and treatment failure in chronic myeloid
leukaemia. Cancers (Basel). 13:21552021.
|
|
150
|
Morse MA, Gwin WR and Mitchell DA: Vaccine
therapies for cancer: Then and now. Target Oncol. 16:121–152.
2021.
|
|
151
|
Pallerla S, Abdul A, Comeau J and Jois S:
Cancer vaccines, treatment of the future: With emphasis on
HER2-positive breast cancer. Int J Mol Sci. 22:7792021.
|
|
152
|
Costa R, Soliman H and Czerniecki BJ: The
clinical development of vaccines for HER2+ breast cancer: Current
landscape and future perspectives. Cancer Treat Rev. 61:107–115.
2017.
|
|
153
|
Al-Awadhi A, Lee MJ and Ibrahim NK:
Developing anti-HER2 vaccines: Breast cancer experience. Int J
Cancer. 143:2126–2132. 2018.
|
|
154
|
Mittendorf EA, Lu B, Melisko M, Price HJ,
Bondarenko I, Brunt AM, Sergii G, Petrakova K and Peoples GE:
Efficacy and safety analysis of Nelipepimut-S vaccine to prevent
breast cancer recurrence: A randomized, multicenter, phase III
clinical trial. Clin Cancer Res. 25:4248–4254. 2019.
|
|
155
|
Disis M, Guthrie KA, Liu Y, Coveler AL,
Higgins DM, Childs JS, Dang Y and Salazar LG: Safety and outcomes
of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in
patients with advanced-stage ERBB2-positive breast cancer: A phase
1 nonrandomized clinical trial. JAMA Oncol. 9:71–78. 2023.
|
|
156
|
Wiedermann U, Garner-Spitzer E, Chao Y,
Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum
C, Yen CJ, Yau TC, et al: Clinical and Immunologic responses to a
B-cell epitope vaccine in patients with HER2/neu-overexpressing
advanced gastric cancer-results from phase Ib trial IMU. ACS.001.
Clin Cancer Res. 27:3649–3660. 2021.
|
|
157
|
Bang K, Cheon J, Park YS, Kim HD, Ryu MH,
Park Y, Moon M, Lee H and Kang YK: Association between HER2
heterogeneity and clinical outcomes of HER2-positive gastric cancer
patients treated with trastuzumab. Gastric Cancer. 25:794–803.
2022.
|
|
158
|
Paterson AL, Shannon NB, Lao-Sirieix P,
Ong CA, Peters CJ, O'Donovan M and Fitzgerald RC: A systematic
approach to therapeutic target selection in oesophago-gastric
cancer. Gut. 62:1415–1424. 2013.
|
|
159
|
Kronig M, Wehrli M, Salas-Benito D and
Maus MV: Hurdles race for CAR T-cell therapy in digestive tract
cancer. Immunol Rev. 320:100–119. 2023.
|
|
160
|
Najafi S and Mortezaee K: Modifying CAR-T
cells with anti-checkpoints in cancer immunotherapy: A focus on
anti PD-1/PD-L1 antibodies. Life Sci. 338:1223872024.
|
|
161
|
Kaczmarek M, Poznanska J, Fechner F,
Michalska N, Paszkowska S, Napierala A and Mackiewicz A: Cancer
vaccine therapeutics: Limitations and effectiveness-a literature
review. Cells-Basel. 12:21592023.
|
